SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences and will also participate in one-on-one investor meetings.
Guggenheim Securities Healthcare Innovation Conference (November 11 – 13, 2024)
Location: InterContinental Hotel, Boston, MA
Format: Fireside Chat
Date and Time: Tuesday, November 12, 2:00 pm Eastern Time
Jefferies London Healthcare Conference (November 19 – 21, 2024)
Location: The Waldorf Hilton, London, UK
Format: Presentation
Date and Time: Wednesday, November 20, 12:30 pm Greenwich Mean Time
7th Annual Evercore HealthCONx Conference (December 3 – 5, 2024)
Location: Loews Coral Gables Hotel, Coral Gables, FL
Format: Fireside Chat
Date and Time: Wednesday, December 4, 11:15 am Eastern Time
A live audio webcast of the events will be available online at Erasca.com/events. An archived replay of the events will be available for 90 days following the webcast at Erasca.com/events.
About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled one of the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
Contact:
Joyce Allaire
LifeSci Advisors, LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.55 |
| Daily Change: | 0.01 0.39 |
| Daily Volume: | 703,259 |
| Market Cap: | US$720.960M |
November 12, 2024 September 25, 2024 August 29, 2024 June 18, 2024 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
